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Abstract
Vascular interstitial cells (VICs) are non-contractile cells with filopodia previously described in healthy blood vessels of rodents and their
function remains unknown. The objective of this study was to identify VICs in human arteries and to ascertain their role. VICs were identified in
the wall of human gastro-omental arteries using transmission electron microscopy. Isolated VICs showed ability to form new and elongate
existing filopodia and actively change body shape. Most importantly sprouting VICs were also observed in cell dispersal. RT-PCR performed on
separately collected contractile vascular smooth muscle cells (VSMCs) and VICs showed that both cell types expressed the gene for smooth
muscle myosin heavy chain (SM-MHC). Immunofluorescent labelling showed that both VSMCs and VICs had similar fluorescence for SM-MHC
and aSM-actin, VICs, however, had significantly lower fluorescence for smoothelin, myosin light chain kinase, h-calponin and SM22a. It was
also found that VICs do not have cytoskeleton as rigid as in contractile VSMCs. VICs express number of VSMC-specific proteins and display fea-
tures of phenotypically modulated VSMCs with increased migratory abilities. VICs, therefore represent resident phenotypically modulated
VSMCs that are present in human arteries under normal physiological conditions.
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Introduction
The primary function of vascular smooth muscle cell (VSMC) in adult
animal is contraction which is necessary for maintaining vascular
tone and control of the blood flow. In contrast with skeletal and stri-
ated muscle cells, VSMCs are not terminally differentiated and can
change their phenotype in response to environmental cues. The
phenotypic modulation or “switch” in VSMCs is accompanied by
accelerated migration, proliferation and production of extracellular
matrix components [1]. In such state, VSMCs are referred to as “syn-
thetic” or phenotypically modulated VSMCs (PMVSMCs). It is estab-
lished that PMVSMCs play a key role during vascular injury and other
pathological conditions of blood vessels. The latter includes a number
of proliferative cardiovascular diseases such as atherosclerosis,
hypertension, diabetic vascular complications and restenosis after
angioplasty or bypass [2]. It is believed that contractile VSMCs either
proliferate at very low rate or do not proliferate at all as the vast
majority of VSMCs observed in mitosis were at least partially modu-
lated towards the “synthetic” state containing few myofilament bun-
dles and a large number of organelles such as free ribosomes and
rough endoplasmic reticulum [3]. These observations suggest that
phenotypic modulation from the contractile towards the synthetic
state is a necessary condition for a proliferation of VSMCs in blood
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vessel. The change in the state of VSMCs from contractile to synthetic
phenotype is accompanied with a decrease in expression of VSMC-
specific proteins, such as aSM-actin, smooth muscle myosin heavy
chain (SM-MHC), SM22a, h1-calponin, smoothelin, caldesmon and
telokin [1]. Most importantly, all these proteins, except SM-MHC, can
be expressed, at least transiently, by other types of cells of the blood
vessel wall [2]. This makes unambiguous identification of PMVSMCs
very difficult. Also, due to substantial heterogeneity within the popula-
tion of VSMCs in disease and the absence of efficient specific markers
for PMVSMCs or VSMCs at various stages of phenotypic modulation,
it is very difficult to obtain “pure” samples of PMVSMCs. This
impedes the employment of efficient molecular biology techniques
that could lead to either establishing specific transcription mecha-
nisms governing phenotypic modulation in vivo, or identification of
highly specific markers for PMVSMCs in disease. Because of above
reasons, the majority of the studies of PMVSMC in pathology relies
on immunofluorescent labelling using VSMC-specific markers in mul-
ticellular preparations or using of the culture of VSMCs as a closest
surrogate for in vivo phenotypic modulation of VSMCs.
Recently, the presence of a new type of cell, called vascular inter-
stitial cells (VICs), was reported in various blood vessels of rodents,
including veins and arteries [4–7]. These non-contractile cells often
had an irregularly shaped body and displayed the presence of the
multiple filopodia. Vascular interstitial cells were observed under nor-
mal physiological conditions either after dispersal of the blood ves-
sels by proteolytic enzyme treatment or in the wall of blood vessels
using transmission electron microscopy (TEM) suggesting that their
appearance is not an artefact of cell isolation [4, 6, 7]. The population
of these cells in blood vessels from animals could be quite substan-
tial; their number can reach up to 5% of total number of contractile
VSMCs in the dispersal of various blood vessels [6]. Freshly dis-
persed VICs from animal blood vessels expressed smooth muscle
myosin heavy chain (SM-MHC), which is a specific marker for the
VSMC phenotype [7, 8]. This suggests that VICs and VSMCs belong
to the same type of cells. Vascular interstitial cells were identified in
number of blood vessels from rodents and it was proposed that VICs
can be present in all blood vessels [6]. In this study, we established
that VICs are also present in human blood vessels. We also addressed
the important questions whether human VICs share the properties of
VICs previously described in animal vasculature and whether these
cells demonstrate the features of the putative phenotypically modu-
lated VSMCs. The preliminary account of this study was presented in
an abstract form at Atherosclerosis, Thrombosis and Vascular Biology
2011 Scientific Sessions.
Materials and methods
Vascular tissue retrieval
This investigation conforms to the principles outlined in the Declaration of
Helsinki and was approved by the local Research Ethics Committee (09/
H0803/103) for retrieval of human blood vessels. In this study, we used
samples obtained from 12 non-diabetic and non-hypertensive patients (3
males and 9 females, average age 56 ± 4 years) undergoing abdominal
surgery. Prior to surgery, the consents were obtained from patients for
using of small fragment of healthy visceral adipose tissue. The adipose
tissue containing branches of human gastro-omental arteries was dis-
sected during surgery, and immediately placed into ice-cold (4°C) physio-
logical saline solution (PSS) of following composition (mmol/l): KCl 6,
NaCl 120, MgCl2 1.2, CaCl2 2.0, D-glucose 10 and HEPES 10; pH was
adjusted to 7.4 with NaOH. The samples were kept in ice-cold PSS and
dissected in the laboratory within 1 hr after dissection. Arteries were iden-
tified as the muscular vessel running as a pair with thin walled veins. The
small (normally smaller than 700 lm in diameter) branches of gastro-
omental arteries were thoroughly cleaned of fat and connective tissue and
used in experiments. Some fragments of blood vessels from every patient
were fixed and their cross-sections were later examined under light micro-
scope. All samples from patients displaying any visible alterations of the
vessel wall such as presence of atherosclerotic lesions were not included
in the study. Samples of cross-sections of omental tissue stained with
haematoxylin and eosin and displaying general architecture of arteries are
shown in Figure S1 in Supporting Information.
Single cell isolation
Single cells were obtained by enzymatic dispersion of fragments of
arteries as we described previously [9]. Briefly, fragments of blood ves-
sels were cleaned of fat and connective tissue were incubated in Ca2+-
free PSS containing 1 mg/ml collagenase type IA, and 0.5 mg/ml
thermolysin type X (both Sigma-Aldrich, Poole, UK) for 30 min. at 37°C
following 5 min. wash in enzyme-free solution. The single cells were
obtained by gentle agitation with Pasteur pipette and then allowed
15 min. to attach to glass coverslip forming the bottom of experimental
chamber. The Ca2+ concentration in chambers was gradually increased
to 2 mmol/l which prevented the myocytes from ‘calcium shock’ and
hypercontraction [10]. After isolation, cells were either collected within
3 hrs for molecular biology experiments, or fixed within 1 hr for immu-
nocytochemical labelling.
Scanning and transmission electron microscopy
Scanning and transmission electron microscopy was preformed
as described in our previous studies [7] and described in detail in
supplementary methods.
Reverse trancription polymerase chain reaction
For RT-PCR, isolated VSMCs and VICs (~150 cells each) were collected
separately using a glass pipette attached to micromanipulator (Support-
ing Information Video S1) and frozen on dry ice immediately. Total RNA
was extracted using RNeasy extraction kit (Qiagen, Crawley, UK) and
cDNA was obtained using Superscript II Reverse Transcriptase (Invitro-
gen, Paisley, UK) and used in PCR. cDNA was used as a template for
PCR reaction using platinum Taq DNA polymerase (Invitrogen). Amplifi-
cation was performed according to the following schedule using a T3
Thermocycler (Biometra, Germany): 94°C for 2 min.; 40 cycles of 94°C
for 30 sec.; 57°C for 60 sec.; and 72°C for 3 min., followed by a final
elongation period of 10 min. at 72°C. No-template control PCR was also
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performed simultaneously with every reaction. Primers were designed
so that they spanned at least one intron of the genomic sequence to
avoid detecting genomic DNA contamination. The experiments were
repeated with three preparations from different patients of independently
collected VICs and VSMCs. The primers were designed to amplify the
genes encoding proteins of interest. The PCR products were separated
and visualized in ethidium bromide-stained 2% agarose gel by electro-
phoresis.
Immunofluorescent analysis
Immunofluorescent analysis was performed as described previously [7, 8].
Single cells were fixed with 4% formaldehyde solution at 4°C for 4 min.,
washed with PSS and incubated with PSS containing 2% bovine serum
albumin (BSA) and 0.3% Triton X-100. Then, samples were incubated with
primary antibodies in PSS containing 2% BSA overnight at 4°C, washed
with PSS and incubated for 2 hrs with secondary antibodies conjugated
with fluorescent probes. Samples were washed with PSS, and viewed using
the laser scanning confocal microscope Zeiss LSM 510 (Zeiss, Oberko-
chen, Germany). For the list and dilutions of the antibodies used, see online
data supplement.
Confocal imaging data were processed and analysed using Zeiss LSM
software. An image taken approximately in the middle of the cell was selected
out of the z-stack of horizontally taken images [8]. Using such an image the
average pixel fluorescence (APF) was calculated according to equation:
AFP ¼
P
iðpÞ
nðpÞ (intensity units/pixel)
where i(p) is the intensity of a pixel within the confocal plane of the
cell, and n(p) is the total number of pixels of the plane. Average pixel
fluorescence values obtained from each VIC and each VSMC were
normalized to the mean APF value derived from all VSMCs in each
experiment (sample). The collective means for VICs and for VSMCs for
each protein from different samples obtained from different patients
were then calculated and the differences statistically compared. Such
approach allowed to visually demonstrate the difference in the expres-
sion of markers between two cell types in data summarized from more
than one patient and to diminish any possible variation in conditions
of experiments. Statistical evaluation and graphs were created using
Origin (OriginLab, Northampton, MA, USA) and final images were pro-
duced using Corel Draw 7.
Statistical analysis
All data is shown as a mean ± SEM for the number of cells (n)
analyzed. Statistical significance was calculated using Student’s t-test
for unpaired observations and the differences where P < 0.05 were
considered significant.
Materials
All general chemicals including proteolytic enzymes were purchased
from Sigma-Aldrich. Molecular biology reagents and primers were pur-
chased from Invitrogen, apart from RNeasy extraction kit which was
purchased from Qiagen. All primary antibodies were purchased from
Abcam (Cambridge, UK) and secondary antibodies were purchased
from Mobitec (Go¨ttingen, Germany). BODIPY 558⁄568 phalloidin was
purchased from Invitrogen.
Results
Morphofunctional characteristics of VICs
The enzymatic dispersion of small human gastro-omental arteries
resulted in cell suspension containing contractile VSMCs and cells
with morphological characteristics similar to VICs previously
described in animal blood vessels (Fig. 1A and B). Vascular inter-
stitial cells were observed in every dispersal of human arteries as
cells with filopodia that often had a multi-polar body (Fig. 1B).
Freshly dispersed VICs from human arteries were also non-con-
tractile: in contrast with VSMCs they did not contract in response
to application of 10 mmol/l caffeine which at this concentration
acts as a very potent spasmogen. In contrast, contractile VSMCs
always contracted in response to application of the drug (Support-
ing Information Figure S1). To confirm the presence of VICs in the
wall of human arteries we employed TEM. These experiments
revealed that cells with similar morphological characteristics are
present within the wall of blood vessels thus, confirming that
A C Ci
Ci
B
Fig. 1 Identification of VICs in small
branches of human gastro-omental artery.
Scanning electron micrographs of single
VSMC (A) and VIC (B) obtained by enzy-
matic dispersion. Note the absence of
filopodia in VSMC. (C) Transmitted electron
micrographs reveal VICs as darker irregu-
larly shaped cells with numerous filopodia
in the wall of the vessel. (Ci) shows
enlarged image of boxed region in (C) at
higher magnification. RBC: red blood cell;
EC: endothelial cell.
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appearance of freshly isolated human VICs is not an artefact of
enzymatic dispersion procedure (Fig. 1C). Further TEM study of
VICs and VSMCs revealed that VICs in human gastro-omental
arteries form numerous cell-to-cell contacts with adjacent VSMCs
and have significantly larger number of calvolae in comparison
with VSMCs, particularly where sides of VIC were facing sides of
VSMCs (Fig 21i–1iii). In addition, the size of the dense bodies in
VICs normally did not exceed 1 lm in its highest x–y dimension,
whereas in VSMCs the dense bodies looked more contrast and
some of these could exceed more than 3 lm in its highest x–y
dimension.
Observation under bright field microscope showed that VICs
from human arteries actively changed their shape within the first
hour after cell isolation. These changes included the extension of
existing filopodia and the formation of new filopodia, as well as
expanding and retracting of the cell body (Fig. 3, Supporting
Information Video S2). It is noteworthy, that the speed and occur-
rence of such changes in VICs decreased with time, and usually
little changes were observed after 2 hrs after isolation. Most
importantly, VICs which have formed bud-like structures from
their filopodia were occasionally observed in cell dispersal within
the same time interval (Fig. 4). Similar structures are observed
in vitro and in vivo in sprouting endothelial cells during angiogen-
esis and their appearance indicates the cellular migration leading
to formation of new endothelial cells [11, 12]. In addition, newly
formed filopodia were observed in bud-like structures (Fig. 4iii)
further suggesting that VICs have higher migratory abilities
compared with those of VSMCs as an abundance of the filopodia
on sprouting endothelial cells or on axonal growth cone is an
indicative of the active migratory phenotype [13–15]. In contrast,
contractile VSMCs during the same period of observation did not
demonstrate significant changes of their body (Supporting Infor-
mation Figure S3), although some contraction of VSMC towards
the central part of the cell was occasionally observed. This was
likely caused by an increase in extracellular calcium concentration
after isolation (see Methods).
Expression of lineage markers in VICs from
human vessels
To confirm the type of cell to which VICs from human arteries belong
to, we employed RT-PCR analysis using cDNA obtained from sepa-
rately collected VSMCs and VICs (~150 cell each type) (Fig. 5). Simi-
lar to VSMCs, VICs showed the expression of SM-MHC, which is a
highly specific marker for smooth muscle type of cell [1], suggesting
that VICs represent phenotypically modulated VSMCs. VICs did not
express genes for other types of cell that can be found in the vascular
wall such as neurons, fibroblasts, pericytes, endothelial cells or mac-
rophages. VICs did not express c-kit gene encoding stem cells factor
protein, previously reported in wall of various, including human,
blood vessels [16–20]. VICs also did not express the gene for another
stem cell marker, CD133, which is expressed in endothelial progenitor
cells [21] and detected in human progenitor cells of atherosclerotic
lesions [22].
Expression VSMC-specific proteins in VICs
It is considered that traditional PMVSMC are characterized by
decreased expression in a number of VSMC-specific proteins. As it
was impossible to obtain sufficient amount of material from manually
collected freshly isolated cells to analyse the expression of proteins
using the western blot technique, we analyzed the expression of
Fig. 2 Transmission electron microscopy (TEM) characterizations of
VICs and VSMCs in the wall of human gastro-omental arteries. Approxi-
mate cross-sections of blood vessels. Top panel shows the architecture
of the blood vessel; (s) depicts VSMC, (V) – VICs, (EC) – endothelial
cells, (BM) -basal elastic membrane separating endothelium and smooth
muscle layers, (CT) – connective tissue in adventitial layer of the blood
vessel. VIC depicted by dashed pink rectangle is shown enlarged in (1).
(n) indicates nucleus, (db) – dense bodies, (f) – filopodia. VIC forms
tight contacts (ctc) with VSMCs (enlarged in 1i-1iii) and significantly
larger number of caveolae (c) compared to VSMCs which is shown
enlarged in (2).
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VSMC-specific proteins in both freshly isolated VICs and VSMCs
using fluorescent immunocytochemistry approach. The analysis of
fluorescence in both types of cells showed that VICs and VSMCs dis-
played similar mean pixel fluorescence for SM-MHC (90 ± 7% in
VICs to that of VSMCs, P > 0.05; 31 VSMCs, 28 VICs; from 3
patients), aSM-actin (93 ± 7% in VICs, P > 0.05; 31,29;3), myosin
light chain (MLC) (99 ± 10% in VICs, P > 0.05; 32,32;3) and h-cal-
desmon (94 ± 8% in VICs, P > 0.05; 27,22;2), (Fig. 6A). VICs, how-
ever, had significantly lower fluorescence for smoothelin (33 ± 3% in
VICs, P < 0.001; 33,31;3), myosin light chain kinase (MLCK)
(27 ± 3% in VICs, P < 0.001; 28,22;2) and calponin (0.13 ± 0.03 in
VICs, P < 0.001; 33,31;3). Very little of fluorescence was observed
for SM22a (0.04 ± 0.01 in VICs, P < 0.001; 34,34;3). The latter four
proteins are considered as markers of mature VSMC [23–27], sug-
gesting that VICs may represent de-differentiated or immature
VSMCs.
The presence of stress fibres in VICs from
human arteries
During the manual collection of isolated cells with a glass micropipette
for molecular biology experiments (see Methods), it was observed that
VICs do not have cytoskeleton as rigid as in VSMCs. Thus, VICs easily
passed into the pipette with the diameter of the tip less than half of the
diameter of these cells (Supporting Information Figure S4. A1–3,
Video S3). In contrast, VSMCs similar in size to VICs occluded pipette
with the same size orifice (Supporting Information Figure S4. B1–3,
Video S3). These observations suggest that the organisation of cyto-
skeletal proteins in VICs is different from that in VSMCs.
It is considered that aSM-actin is the most abundant contributor
to the cytoskeleton of VSMC [1]. The changes in assembly and disas-
sembly of another cytoskeletal protein, f-(fibrillar)-actin, are consid-
ered as the driving process behind phenotypic changes of VSMC
[28]. Therefore, a spatial distribution of these two cytoskeletal pro-
teins was assessed in VICs and VSMCs using high-resolution laser
scanning confocal microscopy. For this purpose fixed preparation of
freshly isolated cells were labelled with the fluorescent probe BODIPY
558⁄568 phalloidin to f-actin and with a specific antibody to detect
aSM-actin. These experiments showed that in human arterial VICs,
aSM- and f- actins are organized into strands running along the cell’s
axis (Fig. 7B and D). In contrast, in contractile human VSMCs, F- and
aSM- actins were more densely packed and it was impossible to iden-
tify individual strands at the same or higher resolution of the confocal
microscope (Fig. 7A and C).
Discussion
During the last several years we have observed that VICs are present
under normal physiological conditions in all blood vessels [6]. These
included small arteries such as resistance mesenteric, kidney or cere-
bral arteries from mouse, rat, guinea pig and rabbit, as well as large
vessels such as rat or mouse mesenteric artery and aorta or rabbit
portal vein. In this study, we confirmed the presence of such cells
under normal conditions in small branches of human gastro-omental
A
B
Fig. 3 VICs actively change their shape,
form new and extend existing filopodia
after isolation. (A) shows VIC during
20 min. of live imaging at room tempera-
ture. Small black arrows indicate the posi-
tion of the tips of filopodia at the start of
the recording, white arrows point to the
parts of the cell body, which display
change in shape. Large black arrows indi-
cate formation of new filopodia. (B) shows
enlarged region of VIC depicted by white
dashed rectangle in (A) shown at higher
magnification. Horizontal bar corresponds
10 lm.
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artery. These findings allow us to assume that such cells are present
in all major mammalian blood vessels, although the presence of VICs
is not confirmed in smaller blood vessels such as arterioles. VICs
from various vascular beds express specific marker of contractile
VSMCs, SM-MHC, and do not express markers of other cell types
present in the wall of blood vessels [8], suggesting that VICs
represent phenotypically modulated VSMCs [7]. VICs from all blood
vessels from different species have at least four major distinct mor-
pho-functional features which differ them from contractile VSMCs:
(1) they are non-contractile; (2) they have multiple filopodia and often
irregularly-shaped multipolar body; (3) VICs form new and extend
existing filopodia, and actively changing the shape of their bodies
after isolation, whereas a shape of the contractile VSMCs remains rel-
atively static during same period of observation; (4) VICs do not have
a cytoskeleton as rigid as in contractile VSMCs and their cytoskeleton
has well-defined dense actin stress fibres. Such stress fibres normally
observed in VSMCs only after several days in the culture [29]. VICs
also showed decreased expression of number of VSMC-specific pro-
teins including smoothelin and SM22a which were reported as indica-
tors of phenotypic modulation of mature/contractile VSMCs in vitro
and disease [26, 30–33]. These observations allow us to suggest that
VICs are a specialized group of phenotypically modulated or de-differ-
entiated VSMCs that are constitutively present in all major blood ves-
sels and share similar morphological and likely functional properties.
Our TEM experiments showed that VICs have significantly larger
number of caveolae than VSMCs which is similar to our previous TEM
observation of VICs and VSMCs from rat cerebral arteries [7]. Inter-
estingly, we observed that in VICs from rat mesenteric arteries the
gene expression for caveolin-1, which is normally localized to caveo-
lae in VSMCs [34], was significantly (hundred times) higher than in
contractile VSMCs (unpublished observation), suggesting that such
difference in caveolae expression can possibly be attributed with VICs
in all blood vessels. Notably, the opposite situation was reported in
cultured VSMCs where the number of caveolae was found to be dis-
tinctly reduced when smooth muscle cells shift from a contractile to a
synthetic phenotype [35]. In addition, we observed that size of dense
bodies, which are normally associated with structural proteins such
as actin and myosin, in VICs normally did not exceed 1 lm, whereas
Fig. 4 Sprouting VIC in cell dispersal from
human arteries. The transmitted light
image shows sprouting VIC in cell dis-
persal from human gastro-omental artery.
Insets (i), (ii) and (iii) show enlarged
regions of VIC depicted by dashed rectan-
gles. White arrows indicate formations of
buds from filopodia, black arrows indicate
the presence of new filopodia in buds.
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in VSMCs dense bodies exceeding 3 lm were observed. This charac-
teristic of VICs could be similar to that reported in synthetic myocytes
where thick myofilaments observed in contractile VSMCs were no
longer observed in myocytes after 7 days in the culture [36].
It is traditionally accepted that synthetic smooth muscle cells are
characterized by downregulation in expression of smooth muscle
specific proteins compared to contractile VSMCs [1, 37, 38]. It is
noteworthy, that majority of these data were obtained using the cul-
ture of VSMCs. Our immunocytochemical experiments showed that
although some proteins such as calponin, sm22a, MLCK and
smoothelin were downregulated in VICs, the expression of two major
VSMC-specific proteins, aSM-actin and SM-MHC, were not downreg-
ulated compared to contractile VSMCs. These observations may sug-
gest that: (1) VICs cannot be detected in the blood vessel wall using
most common markers such aSM-actin and SM-MHC (2) mecha-
nisms governing phenotypic modulation of VICs (in vivo) are likely
different from those for synthetic VSMCs in the culture (in vitro).
Polymerized actin in migrating cells is organized in three major
subtypes: stress fibres, lamellipodia and filopodia. These contractile
structures are thought to generate driving forces forwarding move-
ment of the cell [39]. Freshly dispersed VICs from human arteries
show the presence of actin stress fibres and filopodia, whereas
contractile VSMCs do not have such features. Moreover, an abun-
dance of the filopodia on sprouting of endothelial cells or on axonal
growth cone is an indicative of the active migratory phenotype [14,
15]. In addition, migrating VSMCs during remodelling of blood ves-
sels such as coronary artery VSMCs in restenosis, change their cell
shape and form filopodia. [40]. One of the most important features
observed in VICs from human blood vessels is an ability to change
the shape of their body after enzymatic dispersion of blood vessels
wall. The growth of new and the extension of existing filopodia as
well as expanding and retracting of the body of the freshly isolated
cell (Supporting Information Video S1) are the processes that
undoubtedly characterises VICs as PMVSMCs with increased migra-
tory ability compared to that of VSMCs. We also observed newly
formed filopodia in sprouting of VICs (Fig. 4iii) that further con-
firms that VICs have higher migratory abilities compared to those
of VSMCs as an abundance of the filopodia on sprouting endothe-
lial cells or on axonal growth cone is an indicative of the active
A
B
C
Fig. 5 RT-PCR from separately collected VICs and VSMCs. The following
primers were designed to amplify genes associated with certain cell
types: SM-MHC (SMCs), CD34 (fibroblasts and ECs), PGP9.5 (neurons),
P4H (fibroblasts), NG2 (pericytes), CD68 (macrophages), c -kit (intersti-
tial cells of Cajal), cd133 (stem cells). b-actin was used as a positive
control. (A) primers specificity was tested using human brain cDNA.
(B), (C), VICs and VSMCs showed the presence of SM-MHC suggesting
that VICs belong to VSMC type.
A
B C
Fig. 6 Immunofluorescent analysis of VSMC-specific proteins expression
in VSMCs and VICs. (A) graph of mean pixel fluorescence in VICs nor-
malized to its value in VSMCs. The following proteins were detected:
SM-MHC (31 VSMCs, 28 VICs; from 3 patients) aSM-actin (31,29;3),
MLC (32,32;3), h-caldesmon (27,22;2), calponin (33,31;3), smoothelin
(33,31;3), SM22a (34,34;3), MLCK (28,22;2). ***- indicates P < 0.001.
(B) shows representative images of isolated cells labelled for SM-MHC
(B) and SM22a (C). i – indicates transmitted light, ii – fluorescent
images.
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migratory phenotype [14, 15]. Moreover, the absence of stiff cyto-
skeleton in VICs comparing to VSMCs, even further confirms
these implications. Although the speed of growth of filopodia and
number of all changes in the shape of VICs decreased with time
in isolated VICs, such decrease may be related to an absence of
continuous external supplies of cellular nutrients and building
components in extracellular solution, and/or the absence of suffi-
cient stimuli to maintain further development of these processes
after the maximal adherence of VICs to the bottom of an experi-
mental chamber has occurred. Most importantly, the presence of
sprouting VICs in dispersal indicates that these cells may repre-
sent phenotypically modulated VSMCs with increased proliferative
abilities as sprouting of endothelial cells is associated with their
proliferation during angiogenesis and VICs display formation of
similar sprouts and formation of new filopodia on such sprouts.
Considering the fact that cell migration is sensitive to the prolifer-
ative state of VSMCs and non-proliferating cells in culture are not
migratory [41, 42] we suspect that VICs have higher proliferative
abilities than SMCs and this concept will be investigated in our
future studies.
We can hypothesize that in blood vessels in response to certain
condition (e.g. a disease or tissue injury) the active changes in
shape of VICs may lead to the formation of stalk cells by utilizing
VIC’s filopodia, similarly to the sprouting of endothelial cells during
blood vessel formation [14, 43, 44]. Stalk cells, in turn, may form
either new VICs or replace apoptotic VSMCs. In this case VICs may
play the role of precursors or progenitors of VSMCs in the wall of
blood vessels. Although the possible presence of vascular progenitor
cells in blood vessels have been extensively discussed (see review
[45]) and the presence of potential VSMCs progenitor cells was
reported in tunica adventitia of aorta of ApoE-deficient mice [46],
there is no direct evidence of presence of VSMC- progenitors in the
tunica media of the blood vessel wall. It was proposed that there
may be several distinct types of smooth muscle progenitor cells nor-
mally resident in the adult artery wall with the ability to respond to
injury or disease-promoting stimuli and differentiate into VSMC-like
cells in vivo [47]. It is quite possible that VICs can serve as VSMC
precursors in the media of the blood vessel.
Using transmitted electron microscopy technique, VICs were pre-
viously detected in the tunica media of the blood vessel of rodents [7,
8] and this was confirmed in our present study in human arteries.
Some of these VICs were detected in close proximity to the elastic
membrane of the blood vessel wall. Considering the fact, recent stud-
ies confirmed that VSMCs in atherosclerotic plaques are exclusively
A
C D
Di
Di
B
Bi
Bi
Fig. 7 Immunofluorescent detection of
aSM-actin (A, B) and f-actin (C, D) in
VSMCs (A, C) and VICs (B, D). No individ-
ual stress fibres were observed in VSMCs
where these proteins were densely
packed. Note, that higher concentrations
of aSM-actin were observed in superficial
region of the VSMC (A). VICs showed the
presence of the stress fibres containing
aSM-actin and f-actin. (Bi) and (Di) show
enlarged images of insets in (B) and (D).
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derived from the local vessel wall in apoE-deficient mice [48], it is
attractive to speculate that sprouting VICs may contribute to neointi-
mal thickening of the vessel wall in certain pathological conditions (e.
g. during atherosclerosis). The rapid response of VICs, by changing
the shape of the cell body and sprouting, to the external stimuli,
which in our situation is dispersion of the blood vessel into single
cells, allows us also hypothesize that in blood vessel VICs may con-
tribute to the vascular remodelling in response to the vascular injury.
It deserves mentioning, that filopodia also is one of the
definitive features of interstitial cells of Cajal in visceral smooth
muscle [49–52] as well as in other interstitial-like cells, or telo-
cytes [53] recently described in other tissues such as in uterus
[54, 55], pancreas [56], skeletal muscle interstitium [57], epicar-
dium [58] and endocardium [59], bronchioles [60] and parotid
glands [61]. As no clear role for filopodia or telopodes [53] in
these cells has been determined yet, it is quite possible that
these cellular protrusions may serve as an indicator of increased
migratory abilities of these cells in different tissues. Notably,
recent work by Manole et al. implicated that telocytes may be
involved in neo-angiogenesis after myocardial infarction [62].
This further suggests that establishing the role of interstitial
cells in tissue remodelling during injury is necessary to prove
this hypothesis.
In this study we, for the first time, confirmed that VICs are
PMVSMCs that are constitutively present in the human blood vessels.
The presence of phenotypically modulated VSMCs necessary for
maintenance and remodelling of blood vessels under normal physio-
logical conditions has previously been suggested [63] and it is possi-
ble that VICs may represent such cells in the vascular wall. To further
explore their migratory properties and proliferative properties, the
effect of different extracellular media and various factors affecting
proliferation and migration of VSMCs on freshly dispersed VICs [64]
needs to be studied. Although it was proposed that identification of
PMVSMC is particularly challenging, mainly because of an absence of
the specific marker for these cells [2], VICs represent a group of cells
with multiple features that differ them from contractile VSMCs. We
therefore believe that such differences would be reflected at transcrip-
tional and post-transcriptional levels and thus, the comparative stud-
ies of multiple genes and protein expression are required as the next
step for determining the role of VICs in blood vessels. Such studies
may lead either to discovery of the marker of the phenotypic modula-
tion of VSMCs or to the identification of the important molecular path-
ways controlling mechanisms of the phenotypic modulation in
vascular wall. The creation of the pure culture of VICs may also allow
studying such mechanisms considering that these would be retained
in the culture. VICs therefore may represent a novel model for study
of phenotypic modulation of VSMCs during vascular repair, remodel-
ling and disease.
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Fig. S1. Paraffin embedded cross-sections of the human resistance
gastro-omental arteries stained with haematoxylin and eosin. (A, B)
showing cross-section of the typical arteries used in the experi-
ments from two different patients. The arteries normally displayed
between 3 and 6 layers of smooth muscle cells in medial layer and
presence of some connective tissue in the adventitial layer. (Bi)
shows enlarged fragment of the artery depicted by dashed rectangle
in (B).
Fig. S2. Application of 10 mmol/l caffeine results in contraction of
VSMC but not VIC from human gastro-omental artery. Cells were
pre-loaded with calcium indicator Fluor-3am. (A) transmitted light
image. (B) fluorescence images of Fluo-3 loaded cells (a) before,
(b) at the moment and (c) 10 sec. after 10 mmol/l caffeine appli-
cation. Red and yellow colours indicate increase in intracellular
calcium. Please note the increase in intracellular calcium in
response to agonist in both VSMCs and VICs. Please also note
the contraction of VSMC (white arrow). Horizontal bar corre-
sponds 20 lm.
Fig. S3. Freshly dispersed VSMC from human gastro-omental arter-
ies does not display any significant changes in shape similar to those
recorded in VICs during same period of time. Live imaging per-
formed for 20 min. at room temperature. Transmitted light images
taken with 10 min. interval. Horizontal bar corresponds 10 lm.
Fig. S4. Absence of rigid cytoskeleton in VICs compared to VSMCs.
(A) VIC easily passes into a glass pipette with inner diameter less
than half of the size of the cell. (B) similar in size VSMC blocks the
pipette. Inset (A1i) shows that orifice of the pipette (dashed oval)
is less than 3 lm. A moderate negative pressure is applied to the
pipette. The horizontal bar corresponds 10 lm.
Video S1. Separate collection of isolated VICs and SMCs.
Video S2. Active change in shape of VIC.
Video S3. Absence of rigid cytoskeleton in VIC.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors. Any
queries (other than missing material) should be directed to the corre-
sponding author for the article.
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